TD Cowen analyst Boris Peaker lowered the firm’s price target on Heron Therapeutics to $2.50 from $5.50 and keeps an Outperform rating on the shares. The firm noted Heron anticipates reaching profitability by 4Q 2024 and released updated 2023 and 2024 guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HRTX:
- Heron Therapeutics price target lowered to $4 from $5 at Needham
- Heron Therapeutics sees FY24 revenue $138M-$158M, consensus $156.57M
- Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
- Heron Therapeutics sees Q4 EBITDA, excluding stock compensation, ($10M)-($6M)
- Heron Therapeutics sees FY23 revenue $123M-$125M, consensus $124.61M
